Forsythoside B

SKU: orb1303598

Description

Forsythoside B is a bioactive small molecule that binds lipopolysaccharide (LPS), suppressing NF-κB activation and the subsequent inflammatory cascade. It demonstrates potent neuro- and cardioprotective effects in ischemia-reperfusion injury models, attenuates blood-brain barrier disruption, and exhibits significant antisepsis activity by reducing systemic inflammatory mediators.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 81525-13-5
• MW: 756.70
• Purity: 99.84%
• Formula: C₃₄H₄₄O₁₉
• SMILES: C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO[C@@H]3OC[C@](O)(CO)[C@H]3O)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O
• Target: TNF,NF-κB
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.00 mg/mL (2.64 mM);DMSO:55.00 mg/mL (72.68 mM)

Bioactivity

• In Vivo:
  Intravenous administration of forsythoside B, either alone or in combination with imipenem, significantly diminishes the serum concentrations of TNF-α, IL-6, HMGB1, TREM-1, and endotoxin, while simultaneously increasing the level of IL-10. It also decreases myeloperoxidase (MPO) activity in the lung, liver, and small intestine. Administered at dosages exceeding 8 mg/kg, forsythoside B exhibits considerable neuroprotective effects in rats subjected to cerebral ischemia and reperfusion, with notable efficacy even when administration is delayed by 1 h, 3 h, or 5 h. It reduces brain infarct size and edema, lowers cerebral Evans blue dye leakage and MPO activity, and inhibits expression of cerebral phosphor-IκB-α and NF-κB. Furthermore, forsythoside B at 20 mg/kg significantly enhances myocardial function, evidenced by improved left ventricular systolic pressure (LVSP) and maximal rate of pressure change (±dp/dt(max)), alongside a reduction in myocardial infarct volume, serum Tn-T, TNF-alpha, IL-6 levels, myocardial malondialdehyde (MDA) content, and MPO activity. It also downregulates the protein expression of HMGB1, phosphor-IκB-α, and phosphor-NF-κB, along with mitigating the decrease in superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities. Additionally, forsythoside B, with or without imipenem, lowers CLP-induced mortality rates in rats.
• In Vitro:
  Forsythoside B down-regulates the levels of TNF-α, IL-6 and high-mobility group-box 1 protein (HMGB1) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells, inhibits the IκB kinase (IKK) pathway and modulated nuclear factor (NF)- κB in a concentration-dependently manner.
• Cell Research:
  Forsythoside B is dissolved in sterile saline solution and added to the medium at various concentrations (from 0.1 to 10 μM) and incubated with LPS stimulated RAW264.7 cells. Cell-free supernatants are collected after Forsythoside B treatment for 24 h. Cell viability is assessed by measuring lactate dehydrogenase (LDH) in the medium.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Nuclear factor-kappaB, Nuclear factor-κB, NF-κB, NFkB, NFκB, NF-kB, inhibit, Inhibitor, Forsythoside B, TNFR, TNF Receptor, Tumor Necrosis Factor Receptor

Compound Identifiers

PubChem CID

23928102